All data are based on the daily closing price as of December 24, 2024
s
Sosei Group
4565.TSE
6.58 USD
0.05
+0.77%
Overview
Last close
6.58 usd
Market cap
591.51M usd
52 week high
13.51 usd
52 week low
6.53 usd
Target price
12.99 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
3.1692
Price/Book Value
1.3559
Enterprise Value
716.05M usd
EV/Revenue
3.8401
EV/EBITDA
105.6578
Key financials
Revenue TTM
186.46M usd
Gross Profit TTM
93.27M usd
EBITDA TTM
16.93M usd
Earnings per Share
-0.26 usd
Dividend
N/A usd
Total assets
1.07B usd
Net debt
118.47M usd
About
Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company's development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders. It is also involved in the development of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; and other discovery and preclinical stage drugs. Nxera Pharma Co., Ltd. has a strategic collaboration with AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily; and strategic research and development partnership with PrecisionLife to auto-immune disorders with the potential to identify new drug targets for the treatment of chronic conditions. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Tokyo, Japan.